Endometriosis Treatment Algorithm: Every Line of Therapy Explained

What Is Endometriosis and Why Does Diagnosis Take So Long?

Endometriosis is a chronic, estrogen-dependent inflammatory disease in which tissue resembling the endometrium grows outside the uterine cavity, most commonly on the ovaries, peritoneum, and rectovaginal septum. The displaced tissue bleeds with each menstrual cycle, causing adhesions, scarring, and progressive pelvic pain. Despite affecting an estimated 190 million women globally, the average time from symptom onset to confirmed diagnosis is approximately 7 years.

Why Diagnosis Is Delayed

Several forces compound the delay. Dysmenorrhea is widely dismissed as "normal" menstrual pain, and non-specific symptoms such as bloating, fatigue, and painful intercourse overlap with irritable bowel syndrome and pelvic inflammatory disease. A 2019 survey of 1,120 women found that more than 60% had seen five or more clinicians before receiving a correct diagnosis.

The Gold Standard: Laparoscopy

Laparoscopy with histologic confirmation remains the definitive diagnostic standard per ACOG Practice Bulletin No. 114. Clinical diagnosis based on symptoms and imaging can support empiric treatment but does not replace surgical confirmation when the diagnosis is uncertain. Transvaginal ultrasound and MRI can identify endometriomas and deeply infiltrating disease but miss superficial peritoneal implants.

The Endometriosis Treatment Algorithm: An Overview

Treatment is not one-size-fits-all. The algorithm branches at two key decision points: whether fertility is desired now, and which line of therapy has already been tried. ACOG and ASRM recommend advancing through lines only after an adequate trial at each step.

The framework below reflects that guidance, adapted specifically for women across reproductive years, perimenopause, and post-menopause.

| Line | Therapy | Primary Goal | |------|---------|-------------| | First | NSAIDs, combined hormonal contraceptives (CHC) | Pain control | | Second | Progestins, GnRH agonists/antagonists | Suppress estrogen-driven growth | | Third | Conservative laparoscopic surgery | Excise or ablate lesions | | Fourth | Definitive surgery (hysterectomy ± bilateral oophorectomy) | End disease when childbearing is complete |

First-Line Therapy: NSAIDs and Combined Hormonal Contraceptives

First-line treatment targets pain with the least systemic hormonal burden. Start here unless the patient is actively trying to conceive or has a contraindication to estrogen.

NSAIDs

NSAIDs reduce prostaglandin-mediated dysmenorrhea and are appropriate as monotherapy for mild symptoms. Naproxen sodium 550 mg twice daily or ibuprofen 600 mg three times daily, taken starting 1 to 2 days before anticipated menses, gives better coverage than as-needed dosing. The evidence supporting NSAIDs specifically in histologically confirmed endometriosis is modest; a Cochrane review found insufficient data to confirm superiority over placebo for endometriosis-associated pain, though clinical practice strongly favors their use for primary dysmenorrhea as a first step.

Combined Hormonal Contraceptives

Combined oral contraceptives (COCs), the patch, and the vaginal ring suppress ovulation, reduce menstrual flow, and create a hormonal environment less favorable to ectopic implant growth. Continuous or extended cycling (skipping the placebo week) reduces the frequency of withdrawal bleeds and associated pain flares. A 2018 meta-analysis in Fertility & Sterility found that continuous COC use produced significantly greater pain reduction than cyclic use at 6 months.

Life-stage note for reproductive years: COCs are appropriate as long as you are not trying to conceive and have no contraindication (migraine with aura, personal history of VTE, or uncontrolled hypertension). They do not treat infertility; pause and seek fertility evaluation if pregnancy is the goal.

Life-stage note for perimenopause: Low-dose COCs remain an option for perimenopausal women with endometriosis who are not yet menopausal, providing contraception alongside symptom control. Discuss cardiovascular risk individually with your clinician.

Second-Line Therapy: Progestins and GnRH Agents

When first-line therapy fails after 3 to 6 months, or when the patient has moderate-to-severe disease at laparoscopy, second-line agents provide deeper hormonal suppression.

Progestins

Progestins suppress endometrial tissue by opposing estrogen, inducing decidualization and eventual atrophy of implants. Options include:

• Norethindrone acetate (NETA) 5 mg daily: well-studied in endometriosis, with a 2014 cohort study reporting significant pain reduction in 80% of patients at 6 months.
• Medroxyprogesterone acetate (MPA) depot injection (150 mg every 3 months): highly effective for pain but associated with a prolonged return of fertility (median 10 months after last injection) and bone density loss with long-term use.
• The 52-mg levonorgestrel IUD (Mirena): delivers local progestin with minimal systemic absorption. A 2021 RCT published in the American Journal of Obstetrics and Gynecology found the LNG-IUD reduced endometriosis-associated dysmenorrhea comparably to depot MPA at 12 months, with a more favorable bleeding profile.
• Dienogest 2 mg daily: approved in many countries (though not yet in the US as an endometriosis-specific indication) and supported by multiple RCTs showing non-inferiority to GnRH agonists for pain with less bone loss.

GnRH Agonists

Leuprolide acetate (3.75 mg monthly or 11.25 mg quarterly depot), nafarelin nasal spray, and goserelin implant produce a hypoestrogenic state by downregulating pituitary GnRH receptors after an initial flare. ACOG recommends limiting GnRH agonist monotherapy to 6 months because of bone density loss averaging 1% per month of therapy. Add-back therapy with low-dose estrogen plus a progestin (e.g., norethindrone acetate 5 mg daily) preserves bone mineral density without meaningfully reducing pain control, per the Barbieri add-back principle validated in multiple trials.

GnRH Antagonists: Elagolix and Relugolix

GnRH antagonists block receptors directly, avoiding the initial estrogen flare seen with agonists and allowing dose-titrated partial suppression. Elagolix (Orilissa) was approved by the FDA in 2018 at two doses:

• 150 mg once daily (partial suppression, approved up to 24 months)
• 200 mg twice daily (full suppression, approved up to 6 months)

The ELARIS EM-I and EM-II trials found that at 3 months, 46% of women on elagolix 150 mg and 76% on elagolix 200 mg achieved clinically meaningful reductions in dysmenorrhea, versus 20% on placebo. Bone density loss is dose-dependent; the FDA label recommends the lowest effective dose for the shortest duration necessary.

Relugolix combination tablet (relugolix 40 mg, estradiol 1 mg, norethindrone acetate 0.5 mg, brand name Myfembree) was FDA-approved in 2022 for endometriosis-associated pain and includes built-in add-back therapy, which may reduce bone loss concerns for longer-term use.

Sex-specific pharmacology note: Elagolix is metabolized primarily by CYP3A4. Women taking strong CYP3A4 inducers (rifampin, certain antiepileptics) may have reduced drug exposure. Elagolix also inhibits P-glycoprotein and OATP1B1, a consideration if you are taking statins.

Pregnancy, Lactation, and Contraception: What You Must Know

This section applies to every hormonal treatment listed above. If you are pregnant or planning pregnancy soon, the approach changes completely.

Pregnancy Safety

• Combined hormonal contraceptives: contraindicated in pregnancy. Stop before trying to conceive; fertility returns within 1 to 3 cycles.
• Progestins (systemic, high-dose): most are contraindicated or not recommended in pregnancy. Depot MPA in particular has a prolonged washout. The FDA labels for NETA and MPA carry warnings against use in early pregnancy due to theoretical virilization risk in female fetuses, though data from inadvertent exposures are reassuring.
• GnRH agonists and antagonists: contraindicated in pregnancy. The elagolix FDA label states that elagolix may increase the risk of early pregnancy loss. Women of reproductive potential must use non-hormonal contraception (copper IUD or condoms) while taking elagolix, because the drug itself is not a reliable contraceptive at the 150 mg dose.
• Relugolix combination tablet: contraindicated in pregnancy. Use effective non-hormonal contraception if there is any chance of pregnancy because the built-in add-back hormone dose is insufficient for contraception.

The ASRM Practice Committee states clearly: "Medical therapy for endometriosis does not improve fertility; surgery or ART are the appropriate interventions when conception is the goal."

Lactation

GnRH agonists and elagolix are not recommended during breastfeeding due to insufficient human safety data and the theoretical risk of suppressing prolactin-related milk production. The LNG-IUD is considered compatible with breastfeeding by ACOG because systemic levonorgestrel levels are very low. Progestin-only pills and NETA in low doses are generally considered acceptable during lactation; discuss with your clinician.

If You Are Trying to Conceive

Stop all hormonal suppression therapy and pursue fertility evaluation promptly. If you have not conceived within 6 months of stopping treatment (or 12 months if under 35), referral to a reproductive endocrinologist is appropriate per ASRM guidance.

Third Line: Conservative Laparoscopic Surgery

Surgery is appropriate when medical therapy fails, when an endometrioma is present, when deeply infiltrating disease is confirmed, or when fertility is the primary goal.

Excision vs. Ablation

Laparoscopic excision (cutting out lesions) produces more durable pain relief than ablation (burning the surface) for peritoneal implants. A Cochrane review found that laparoscopic surgical treatment improved pain and quality of life compared to diagnostic laparoscopy alone, with a number needed to treat of approximately 3 for pain improvement.

Surgery and Fertility

For women with endometriosis-related infertility and no other identified cause, ASRM states that surgical treatment of minimal-to-mild endometriosis improves spontaneous pregnancy rates. The ENDOCAN-1 RCT found a spontaneous pregnancy rate of 40% within 3 years after laparoscopic surgery compared to 22% after expectant management in women with stage I-II disease.

Endometrioma surgery carries the risk of reducing ovarian reserve; a 2014 meta-analysis in Human Reproduction found that women who had undergone endometrioma surgery had significantly lower anti-Müllerian hormone (AMH) levels than matched controls. Discuss ovarian reserve testing before any surgical procedure involving the ovaries.

Post-Surgical Medical Therapy

Resuming hormonal suppression (COC or progestin) after conservative surgery reduces the risk of disease recurrence. A 2012 meta-analysis found that post-operative COC use reduced the 5-year recurrence rate from approximately 30% to 15%.

Fourth Line: Definitive Surgery

Hysterectomy with or without bilateral salpingo-oophorectomy (BSO) is reserved for women who have completed childbearing, have failed medical and conservative surgical options, and have persistent disabling disease. Hysterectomy alone without excision of all visible endometriosis leaves residual disease in up to 15% of cases, which can remain symptomatic even after oophorectomy if exogenous estrogen is given without adequate progestin coverage.

Post-Oophorectomy Hormone Therapy

Surgical menopause before age 45 carries significant cardiovascular and bone-health risks. Women who undergo BSO for endometriosis before natural menopause should receive hormone therapy to protect bone density and cardiovascular health. The Menopause Society (NAMS) 2023 Position Statement supports estrogen therapy after oophorectomy for endometriosis, with the addition of a progestin recommended if any uterine tissue remains, to prevent stimulating residual implants.

Life-Stage Guide: Which Path Is Right for You?

Your current life stage changes the risk-benefit calculation at each line of therapy.

Reproductive Years (Ages 18 to 40), Not Trying to Conceive

Begin with NSAIDs plus continuous COC. If pain is inadequately controlled after 3 to 6 months, move to a progestin or GnRH antagonist with add-back. Surgery is a reasonable choice when lesions are confirmed and medical therapy has failed or is not tolerated.

Actively Trying to Conceive

Stop all hormonal suppression. Refer for fertility evaluation early, particularly if you have stage III-IV disease or an endometrioma. Laparoscopic excision before IVF may improve outcomes in some cases, though ASRM guidance notes the evidence is mixed for stage I-II disease.

Postpartum and Lactation

Endometriosis symptoms often improve during pregnancy and in the early postpartum period due to progesterone dominance and lactation-related amenorrhea. Symptoms frequently return with the resumption of menses. The LNG-IUD is a reasonable option during breastfeeding for women who need ongoing suppression.

Perimenopause (Ages 40 to 51)

Hormonal fluctuation in perimenopause can trigger symptom flares. Progestins remain appropriate, and low-dose COCs are an option if no cardiovascular contraindications exist. The natural decline in estrogen approaching menopause may eventually reduce disease activity, but some women experience intensified symptoms during the estrogen-dominant early perimenopausal transition.

Post-Menopause

Endometriosis is generally expected to regress after natural menopause. Postmenopausal recurrence, while uncommon, does occur, particularly in women taking unopposed estrogen therapy. If you are on estrogen-only HT after a hysterectomy for endometriosis, discuss with your clinician whether adding a progestin is advisable to suppress any residual implants.

The Evidence Gap: What We Do Not Know Yet

Women have been historically underrepresented in pain research, and endometriosis research specifically has suffered from small samples, short follow-up, and predominantly white study populations. A 2022 analysis in the American Journal of Obstetrics and Gynecology found that Black women with endometriosis are diagnosed later and are less likely to receive surgical treatment than white women with equivalent disease burden. Most GnRH antagonist trials enrolled fewer than 10% participants from racial or ethnic minority groups. Extrapolating efficacy and safety data to all women requires caution, and your clinician should apply guidelines with that limitation in mind.

"The diagnosis and treatment of endometriosis remain inequitable across racial and socioeconomic lines. Closing that gap requires both better research representation and greater clinical awareness of atypical presentations," according to the ACOG Committee on Gynecologic Practice.

Who This Treatment Path Is Right For (and Who Should Pause)

A good candidate for medical-first management:

• Confirmed or strongly suspected endometriosis with manageable pain
• No immediate fertility plans
• No contraindication to estrogen or progestins
• Willing to trial therapy for 3 to 6 months before reassessing

Pause medical management and see a specialist promptly if:

• You are trying to conceive and have been unsuccessful for 6 months (or 12 months if under 35)
• An endometrioma >4 cm is identified on ultrasound
• You have severe or worsening symptoms that are not controlled at the current line
• You have deep infiltrating disease involving the bowel, bladder, or ureter (requires multidisciplinary surgical planning)
• You are postmenopausal and developing new pelvic pain (rule out malignant transformation, rare but reported)